CMS Offers Two Paths To “Coverage With Evidence” In Revised Guidance
This article was originally published in The Gray Sheet
Executive Summary
CMS introduces two distinct categories of coverage-with-evidence-development determinations in long-awaited 1guidelines issued July 12
You may also be interested in...
Local Coverage With Evidence Development Is Legit, CMS Says; But It May Be Rare
CMS issued its final guidance on the coverage-with-evidence-development program, two years following a draft. It is explicit that local Medicare contractors can employ CED in setting coverage policies in their jurisdictions, but it is not clear that the language will encourage significant use at the local level. The guidance also revises its approach on ending CED policies compared to what was stated in the 2012 draft guidance.
Washington Roundup, January 2013
The latest medical device regulatory and reimbursement news from Elsevier Business Intelligence’s “The Gray Sheet.” This month we cover FDA’s proposal to require PMAs for metal-on-metal hips, the launch of the Medical Device Innovation Consortium, CMS draft guidance on CED, and a recent analysis of the potential impact of the Affordable Care Act on device markets.
CMS Redefines Coverage-With-Evidence-Development In Draft Guidance
The document replaces a 2006 guidance, making substantial changes in response to public comment and six years of experience with the policy. The policy allows for national Medicare coverage under the condition that data be collected on use of the item or service in Medicare beneficiaries.